Point72 Asia (Singapore) Pte. Ltd. Rallybio Corp Transaction History

Point72 Asia (Singapore) Pte. Ltd.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	SELL	$0.61 - $1.05 $7,713 - $13,277	-12,645 Reduced 55.82%	10,007 $6.55 Million
Q4 2024 Feb 14, 2025	BUY	$0.86 - $1.2 $458 - $639	533 Added 2.41%	22,652 $21.7 Million
Q3 2024 Nov 14, 2024	SELL	$1.09 - $1.45 $25,519 - $33,947	-23,412 Reduced 51.42%	22,119 $25.9 Million
Q2 2024 Aug 14, 2024	BUY	$1.34 - $2.98 $61,011 - $135,682	45,531 New	45,531 $61 Million

28.9M

Ticker RLYB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 32,132,000
Market Cap $20.6M
Description
Rallybio Corporation, a clinical-stage biotechnology company, engages in discovering, developing, manufacturing, and delivering therapies that enhance the lives of patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that is in Phase I clinical trial for the prevention of feta...

Get notified when there are updates to the investment portfolio of Point72 Asia (Singapore) Pte. Ltd., based on Form 13F filings with the SEC.

Stay updated on Point72 Asia (Singapore) Pte. Ltd. with notifications on news.